Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.

Zengzhi LianWenwen DuYang ZhangYulong FuTing LiuAnqi WangTingting CaiJianjie ZhuYuanyuan ZengZeyi LiuJian-An Huang

Published in: Thoracic cancer (2020)

FGFR1 overexpression could be the mechanism of EGFR-TKI acquired resistance and anlotinib can suppresse the growth of EGFR-TKI-resistant NSCLC cells without T790M mutation.

Keyphrases

tyrosine kinase
small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
induced apoptosis
brain metastases
cell cycle arrest
cell proliferation
transcription factor
cell death
signaling pathway